Evidence map›Paper›PMID 34089805›Full record

ArticleMolecular and cellular probes2021

Development and validation of a new triplex real-time quantitative reverse Transcriptase-PCR assay for the clinical detection of SARS-CoV-2.

Vijay J Gadkar, David M Goldfarb, Virginia Young, Nicole Watson, Ghada N Al-Rawahi, Jocelyn A Srigley, Peter Tilley

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular probes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vijay J GadkarDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada; Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: vijay.gadkar@cw.bc.ca.
David M GoldfarbDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada; Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Virginia YoungDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada.
Nicole WatsonDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada.
Ghada N Al-RawahiDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada; Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Jocelyn A SrigleyDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada; Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Peter TilleyDepartment of Pathology & Laboratory Medicine, Division of Microbiology, Virology & Infection Control, BC Children's and Women's Hospital + Sunny Health Center, Vancouver, Canada; Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
University of British Columbia · CAB.C. Women's Hospital & Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To increase the repertoire of PCR based laboratory developed tests (LDTs) for the detection of SARS-CoV-2, we describe a new multiplex assay (SORP), targeting the SARS-CoV-2's, Spike and ORF8 genes. The widely used human RNaseP internal control was modified to specifically co-amplify the RNaseP mRNA. The SORP triplex assay was tested on a cohort (n = 372; POS = 144/NEG = 228) of nasopharyngeal flocked swab (NPFS) specimens, previously tested for the presence of SARS-CoV-2 using a PCR assay targeting E and RdRp genes. The overall sensitivity and specificity of the SORP assay was: 99.31% (95% CI: 96.22-99.98%), 100.0% (95% CI: 98.4-100%) respectively. The SORP assay could also detect a panel of variants of concern (VOC) from the B1.1.7 (UK) and B1.351 (SA) lineage. In summary, access to a repertoire of new SARS-CoV-2 LDT's would assist diagnostic laboratories in developing strategies to overcome some of the testing issues encountered during high-throughput SARS-CoV-2 testing.

Indexed as

Clinical Laboratory TechniquesCOVID-19COVID-19 TestingDNA PrimersDNA ProbesHumansMolecular Diagnostic TechniquesMultiplex Polymerase Chain ReactionReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionRibonuclease PSARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusViral ProteinsDNA PrimersDNA ProbesORF8 protein, SARS-CoV-2Ribonuclease PRPP40 protein, humanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral ProteinsLDTORF8RNasePSARS-CoV-2SpikeVariants of concern

Identifiers

PMID34089805
PMCPMC8176879
OpenAlexW3170193809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.